Search studies

ABIRISK

Clinical and anti-drug antibody data from 4 european countries

1

AETIONOMY

Study phase: recruitment. For more details, see http://www.aetionomy.eu/content/dam/scai/AETIONOMY/Dokumente/Aetionomy_Newsletter4_web.pdf

2

APPROACH

All baseline cohort parameters, clinical, conventional (knee x-ray and MRI and the robust biochemical markers), and novel markers (T2 relaxation MRI for cartilage collagen distribution, gagCEST MRIcartilage for proteoglycan content, knee CT/x-ray for bone shape and trabecular architecture, knee motion, and novel biochemical markers describing turnover of specific tissue component, as well as involvement of hand, hip and spine joint damage, hand joint inflammation, hip motion and shape and bon...

3

DIRECT

Interim analysis. Study outline is available in Diabetologia (2014) 57:1132–1142.

4

EBiSC study

The European Bank for induced pluripotent Stem Cells (EBiSC) is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.

5

EBiSC2 study

The European Bank for induced pluripotent Stem Cells (EBiSC) is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.

6

EPAD

Observational Study. More details available at http://datacat.uni.lu/additional_files/EPAD_Study_Protocol_Description.htm

7

IMIDIA study

8